

Datasheet: HCA283 BATCH NUMBER 161834

Description:	HUMAN ANTI DENOSUMAB
Specificity:	DENOSUMAB
Other names:	PROLIA, XGEVA
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD26781_hlgG1
Isotype:	lgG1
Quantity:	0.1 mg

Product Details

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .					
		Yes	No	Not Determined	Suggested Dilution	
	ELISA	-				
	Where this product has necessarily exclude its u a guide only. It is recomi system using appropriate	ise in sucł mended tł	n procedu nat the use	res. Suggested workin er titrates the product f	g dilutions are given as	
Product Form	Human IgG1 antibody (k and expressed in a hum		,	elected from the HuCA	L® phage display library	
Preparation	Purified IgG prepared by	/ affinity cł	nromatogi	aphy on Protein A		
Buffer Solution	Phosphate buffered salir	ne				
Preservative Stabilisers	0.01% Thiomersal					
Approx. Protein Concentrations	IgG concentration 0.5 mg/ml					
Immunogen	Denosumab					
Specificity	Human Anti-Denosuma	ab Antibo	dy, clone	AbD26781_hlgG1 is	a non-inhibitory	

anti-idiotypic antibody that specifically recognizes free human monoclonal antibody drug denosumab, and the drug in complex with its target, RANKL (receptor activator of nuclear factor kappa-B ligand). The antibody does not recognize free RANKL and does not inhibit binding of denosumab to RANKL.

A pair of anti-denosumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay. This antibody clone AbD26781_hlgG1 is recommended as the detection antibody, paired with either clone AbD26295_hlgG1 (HCA280) or clone AbD26862_hlgG1 (HCA282) as capture antibody. It can also be used as the detection antibody in an antigen capture format assay. This antibody is not suitable for the development of an anti-drug antibody (ADA) assay.

Denosumab (Prolia, Xgeva) is a fully human monoclonal antibody (IgG2/kappa) for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone. The drug specifically binds to human RANKL a protein that acts as the primary signal to promote bone removal/resorption and prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors.

View a summary of all anti-denosumab antibodies.

Affinity	The monovalent intrinsic affinity of this antibody was measured as K_D = 19 nM by real time, label-free molecular interaction analysis on immobilized denosumab and as K_D = 17 nM on the RANKL/drug complex.
ELISA	This antibody can be used as a detection antibody in a bridging ELISA together with <u>HCA280</u> or <u>HCA282</u> as capture reagents. This antibody can be used in an antigen capture ELISA. Protocol: <u>PK bridging ELISA to measure free drug.</u>
Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C. Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Guarantee	12 months from date of despatch
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details. Prolia and Xgeva are registered trademarks of Amgen Inc.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA283 10094
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro

	testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u>

Related Products

Recommended Useful Reagents

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK001P) HUMAN ANTI DENOSUMAB (HCA280) HUMAN ANTI DENOSUMAB (HCA282) HISPEC ASSAY DILUENT (BUF049A)

North & South	Tel: +1 800 265 7376	Worldwide
America	Fax: +1 919 878 3751	
	Email: antibody_sales_us@bio-rad.com	

Tel: +44 (0)1865 852 700 Euro Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com

Europe Tel: +49 (0) 8 Fax: +49 (0) 8

Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M391794:211015'

Printed on 19 Feb 2025

© 2025 Bio-Rad Laboratories Inc | Legal | Imprint